Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1
This article originally appeared at https://www.sciencedirect.com/science/article/abs/pii/S0006295214004201 Authors Institute of Toxicology and Pharmacology, University of Rostock, Rostock, GermanybSection of Molecular Oncology and Immunotherapy, Department of General Surgery, University of Rostock, Rostock, GermanycDepartment of Radiotherapy and Radiation Oncology, University of Rostock, Rostock, Germany https://doi.org/10.1016/j.bcp.2014.07.014 Abstract Cannabinoids have been shown to promote the expression of the intercellular adhesion […]
Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma
This article originally appeared at https://jpet.aspetjournals.org/content/318/3/1375 Authors: Alessia Ligresti, Aniello Schiano Moriello, Katarzyna Starowicz, Isabel Matias, Simona Pisanti, Luciano De Petrocellis, Chiara Laezza, Giuseppe Portella, Maurizio Bifulco and Vincenzo Di Marzo Journal of Pharmacology and Experimental Therapeutics September 2006, 318 (3) 1375-1387; DOI: https://doi.org/10.1124/jpet.106.105247
The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells
This article originally appeared at https://gut.bmj.com/content/54/12/1741.abstract Authors: Abstract Background and aims: Cyclooxygenase 2 (COX-2) is upregulated in most colorectal cancers and is responsible for metabolism of the endogenous cannabinoid, anandamide, into prostaglandin-ethanolamides (PG-EAs). The aims of this study were to determine whether anandamide and PG-EAs induce cell death in colorectal carcinoma (CRC) cells, and whether high […]
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation
This article originally appeared at https://www.pnas.org/doi/abs/10.1073/pnas.95.14.8375 Authors: Luciano De Petrocellis, Dominique Melck, Antonella Palmisano, +3, and Vincenzo Di MarzoAuthors Info & Affiliations July 7, 1998 https://doi.org/10.1073/pnas.95.14.8375 Abstract Anandamide was the first brain metabolite shown to act as a ligand of “central” CB1 cannabinoid receptors. Here we report that the endogenous cannabinoid potently and selectively inhibits the proliferation of human breast cancer cells in vitro. […]
Assessing the Tolerability of Two Different Ratios of Medicinal Cannabis in Patients With High Grade Gliomas
This originally appeared at https://www.frontiersin.org/articles/10.3389/fonc.2021.649555/full Authors: Janet Schloss1,2,3*, Judith Lacey4,5,6, Justin Sinclair4, Amie Steel3, Michael Sughrue7, David Sibbritt3 and Charles Teo7 Background: Cannabis for cancer is very topical and, given the use of illicit cannabis preparations used in this vulnerable population, research investigating standardised, quality-assured medicinal cannabis is critical to inform clinicians and assist patient […]
Delta9-Tetrahydrocannabinol inhibits lung cancer cell migration in vitro as well as its growth and metastasis
This article originally appeared at https://www.nature.com/articles/1210641 D9-Tetrahydrocannabinol (THC) is the primary cannabinoid of marijuana and has been shown to either potentiate or inhibit tumor growth, depending on the type of cancer and its pathogenesis. Little is known about the activity of cannabinoids like THC on epidermal growth factor receptor-overexpressing lung cancers, which are often highly […]
Medical Marijuana Legalization and Opioid- and Pain-Related Outcomes Among Patients Newly Diagnosed With Cancer Receiving Anticancer Treatment
This article originally appeared at https://jamanetwork.com/journals/jamaoncology/article-abstract/2799132 Authors Yuhua Bao, PhD1,2; Hao Zhang, PhD1; Eduardo Bruera, MD3; et alRussell Portenoy, MD4,5,6; William E. Rosa, PhD, MBE, APRN7; M. Carrington Reid, MD, PhD8; Hefei Wen, PhD9 JAMA Oncol. 2023;9(2):206-214. doi:10.1001/jamaoncol.2022.5623 Key Points Question Is medical marijuana legalization associated with opioid-related and pain-related outcomes for adult patients newly diagnosed with cancer and receiving anticancer treatment? Findings This cross-sectional study of 38 189 patients […]
CBD From Marijuana Plus Chemotherapy Tripled Cancer Survival Rates In Mice
This article originally appeared at https://www.forbes.com/sites/daviddisalvo/2018/07/31/study-cbd-from-marijuana-plus-chemotherapy-triples-cancer-survival-rates-in-mice/#978586d46303 Mice with pancreatic cancer treated with a combination of cannabidiol (CBD) and chemotherapy survived nearly three times longer than those treated with chemotherapy alone, according to a new study that spotlights the potential for human treatment. CBD, the non-psychoactive (non-intoxicating) compound in marijuana, has already been shown to improve side effects of […]
Medical Marijuana Legalization and Opioid- and Pain-Related Outcomes Among Patients Newly Diagnosed With Cancer Receiving Anticancer Treatment
This article originally appeared at https://jamanetwork.com/journals/jamaoncology/article-abstract/2799132 Yuhua Bao, PhD1,2; Hao Zhang, PhD1; Eduardo Bruera, MD3; et alRussell Portenoy, MD4,5,6; William E. Rosa, PhD, MBE, APRN7; M. Carrington Reid, MD, PhD8; Hefei Wen, PhD9 JAMA Oncol. 2023;9(2):206-214. doi:10.1001/jamaoncol.2022.5623 Key Points Question Is medical marijuana legalization associated with opioid-related and pain-related outcomes for adult patients newly diagnosed with cancer and receiving anticancer treatment? Findings This cross-sectional study of 38 189 patients with […]
Cannabinoids: a new hope for breast cancer therapy?
This originally appeared at https://pubmed.ncbi.nlm.nih.gov/22776349/ a b s t r a c tBreast cancer is a very common disease that affects approximately 1 in 10 women at some point in theirlives. Importantly, breast cancer cannot be considered a single disease as it is characterized by distinctpathological and molecular subtypes that are treated with different therapies […]
